Mark D. Angelino Joins Board of Directors for Arbor Biotechnologies

Mark D. Angelino has been elected as a Member of the Arbor Biotechnologies Board of Directors. He is a veteran executive in the pharmaceutical space with expertise in growth and product development. Currently, Mark is a Venture Partner with Third Rock Ventures. He was previously the Co-Founder and Chief Operating Officer for Generation Bio. Prior to that, he served bluebird bio as Senior Vice President of Pharmaceutical Services and Head of the Rare Disease Franchise. He also spent time with Baxter Healthcare as Senior Director of Research and Development, as well as Site Head for Cambridge, MA.
 
Arbor Biotechnologies is an early-stage company unlocking nature’s genetic diversity to meet the next generation of challenges in the gene editing field. The company is headquartered in Cambridge, MA.